PMID- 35117720
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 9
IP  - 5
DP  - 2020 May
TI  - Knockout of LATS1 induces neoplastic phenotype in hepatic oval cells.
PG  - 3564-3572
LID - 10.21037/tcr-19-2847 [doi]
AB  - BACKGROUND: Primary liver cancer (PLC) is the second leading cause of 
      cancer-related death worldwide. It has been reported that PLC can be originated 
      from malignant transformed adult hepatic progenitor cells. Mammalian large tumor 
      suppressor kinase 1 (LATS1) is one of the core components of the Hippo pathway 
      and it has been implicated in regulating invasion and metastasis of different 
      cancer cell. However, the underlying connections between hepatic progenitor cells 
      and LATS1 in the pathogenesis of PLC are still elusive. METHODS: LATS1 gene 
      knockout (LATS1-KO) hepatic oval cells (HOCs) were constructed by the CRISPR/Cas9 
      system. Cell viability was evaluated by the CCK-8 assay. Cell migration was 
      measured by scrape assay. Cell invasion was examined by Transwell assay. Cell 
      apoptosis was evaluated by flow cytometry. The expression of LATS1 and 
      Yes-associated protein (YAP) in HOCs was determined by Q-PCR and Western blot 
      analysis. RESULTS: Here, we found that knockout of LATS1 significantly induced 
      the migration and invasion of WB-F344 cells. Knockdown of YAP suppressed the 
      neoplastic phenotype of LATS1-KO WB-F344 cells. Furthermore, overexpression of 
      YAP promoted the migration and invasion of LATS1-KO WB-F344 cells. CONCLUSIONS: 
      In summary, the current study demonstrated that LATS1 is required for inhibiting 
      the neoplastic phenotype of normal hepatic progenitor cell via downregulating 
      YAP.
CI  - 2020 Translational Cancer Research. All rights reserved.
FAU - Sun, Qigang
AU  - Sun Q
AD  - Department of Hepatobiliary and Pancreatic Surgery, Hainan General 
      Hospital/Affiliated Hainan Hospital of Hainan Medical College, Haikou 570311, 
      China.
FAU - Wu, Changxiong
AU  - Wu C
AD  - Department of Hepatobiliary and Pancreatic Surgery, Hainan General 
      Hospital/Affiliated Hainan Hospital of Hainan Medical College, Haikou 570311, 
      China.
FAU - Fu, Cexiong
AU  - Fu C
AD  - Department of Hepatobiliary and Pancreatic Surgery, Hainan General 
      Hospital/Affiliated Hainan Hospital of Hainan Medical College, Haikou 570311, 
      China.
FAU - Chen, Pingping
AU  - Chen P
AD  - Department of Hepatobiliary and Pancreatic Surgery, Hainan General 
      Hospital/Affiliated Hainan Hospital of Hainan Medical College, Haikou 570311, 
      China.
FAU - Chen, Cheng
AU  - Chen C
AD  - Department of Hepatobiliary and Pancreatic Surgery, Hainan General 
      Hospital/Affiliated Hainan Hospital of Hainan Medical College, Haikou 570311, 
      China.
FAU - Liu, Jun
AU  - Liu J
AD  - Department of Hepatobiliary and Pancreatic Surgery, Hainan General 
      Hospital/Affiliated Hainan Hospital of Hainan Medical College, Haikou 570311, 
      China.
FAU - Li, Shibing
AU  - Li S
AD  - Department of Pediatric surgery, Hainan General Hospital/Affiliated Hainan 
      Hospital of Hainan Medical College, Haikou 570311, China.
FAU - Zheng, Jinfang
AU  - Zheng J
AD  - Department of Hepatobiliary and Pancreatic Surgery, Hainan General 
      Hospital/Affiliated Hainan Hospital of Hainan Medical College, Haikou 570311, 
      China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8798110
OTO - NOTNLM
OT  - Primary liver cancer (PLC)
OT  - Yes-associated protein (YAP)
OT  - hepatic oval cells (HOCs)
OT  - large tumor suppressor kinase 1 (LATS1)
OT  - migration and invasion
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr-19-2847). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/05/01 00:00
MHDA- 2020/05/01 00:01
PMCR- 2020/05/01
CRDT- 2022/02/04 05:51
PHST- 2019/12/17 00:00 [received]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2022/02/04 05:51 [entrez]
PHST- 2020/05/01 00:00 [pubmed]
PHST- 2020/05/01 00:01 [medline]
PHST- 2020/05/01 00:00 [pmc-release]
AID - tcr-09-05-3564 [pii]
AID - 10.21037/tcr-19-2847 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2020 May;9(5):3564-3572. doi: 10.21037/tcr-19-2847.